TD Cowen raises Twist Bioscience stock price target on revenue beat

TD Cowen raised Twist Bioscience’s price target to $68 from $58 and reiterated Buy, citing Q2 revenue of $111 million, up 19% year over year and ahead of the $108 million consensus. Next-generation sequencing revenue was $57 million (+12%) and DNA Synthesis and Protein revenue was $53 million (+28%), with the firm highlighting AI-driven therapeutics growth of 55% year over year. The company also reported Q2 FY2026 EPS of -$0.71 versus the -$0.48 forecast, so the setup is positive overall but tempered by an earnings miss.

Analysis

TWST is increasingly being valued less like a tools company and more like a capital-light platform leveraged to the AI-drug-discovery cycle. The second-order implication is that incremental demand from therapeutics customers should be higher quality than legacy sequencing demand: once a program is embedded in an assay workflow, switching costs rise and revenue becomes stickier, which supports a higher multiple even if near-term earnings remain noisy.

The key debate is not whether growth is accelerating, but whether the market is already discounting a clean inflection that may still be a few quarters away. If the sequencing customer’s return to growth is transitory or tied to budget timing, the stock can de-rate quickly because the current setup leaves little margin for error after a >90% YTD move. Conversely, if AI-linked therapeutics continues compounding, the market may have to reframe TWST as an enabling infrastructure name with longer-duration growth, not just a cyclical consumables story.

The biggest near-term risk is a sentiment reset from any follow-through EPS disappointment or guidance conservatism; high-growth names with narrow operating leverage often trade on revenue visibility until they can prove durable margin expansion. On the other hand, the current setup creates a good asymmetry for defined-risk expression: the business can keep compounding even if the stock digests gains, but a single quarter of softer NGS or weaker bookings could compress the multiple materially over 1-2 months. Consensus appears to be underweighting how much of the rerating has already happened versus how much actual operating proof is still required.

Key Decisions for Investors

• Sell downside protection via a 1-2 month put spread overwrite only if already long TWST; collect premium against an overextended rally while capping downside in a name with strong fundamental momentum.
• For fresh exposure, wait for a post-earnings consolidation and buy a partial position on a 5-10% pullback over the next 2-6 weeks; risk/reward improves materially versus chasing after a >90% YTD move.
• Pair trade: long TWST / short a slower-growth life-science tools peer basket over 3-6 months, targeting multiple expansion driven by AI therapeutics mix; cut if TWST misses two sequential revenue prints or NGS growth fails to reaccelerate.
• If owning TWST outright, hedge with short-dated calls against a catalyst-rich window; the stock likely remains range-bound near term until management proves margin leverage, creating a good covered-call setup.
• Do not short outright into the current momentum unless you have a catalyst-driven thesis; instead, use a bearish put spread only if guidance implies a stall in the next 1-2 quarters, as upside skew remains elevated while AI narrative persists.